Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ligand Pharm (NQ: LGND )

119.19 +2.64 (+2.27%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharm

< Previous 1 2 3 4 5 6 Next >
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tough Slogging Ahead for Investors, Diversification is Important
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows. 
Via Talk Markets
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 348 companies hit new 52-week lows. Significant Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
Recap: Ligand Pharmaceuticals Q4 Earnings
Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Earnings Scheduled For February 17, 2022
Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. 
Via Benzinga
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel... 
Via Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news... 
Via Benzinga
Ligand to Report Fourth Quarter Financial Results on February 17
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand and GSK Expand Global Collaboration and License Agreement
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Meme Stock Breakdown
There have been plenty of market happenings and themes in 2021 but perhaps one of the more intriguing ones was the recurring bouts of meme stock mania. 
Via Talk Markets
Ligand Pharmaceuticals Sees RS Rating Rise To 92
A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance. 
Via Investor's Business Daily
Ligand To Spin-Off OmniAb Platform Into Its Own Independent Company
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced plans to split into two separate publicly traded companies. One company will feature the OmniAb... 
Via Benzinga
Ligand Pharmaceuticals Incorporated (LGND) Q3 2021 Earnings Call Transcript
LGND earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: Ligand Pharmaceuticals Q3 Earnings
Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:01 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Ligand Reports Third Quarter 2021 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Report Third Quarter Financial Results on November 9, 2021
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Outlicenses BEPro Tech To Develop Oral COVID-19 Antivirals
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has signed a collaboration agreement with Double-Crane Pharmaceutical Co Ltd (CRDC). The agreement grants... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™
From Ligand Pharmaceuticals Incorporated
Via Business Wire
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Ligand Pharmaceuticals Stock Shows Rising Price Performance
A Relative Strength Rating upgrade for San Diego-based Ligand Pharmaceuticals stock shows improving technical performance. 
Via Investor's Business Daily
Ligand Pharmaceuticals Stock Shows Market Leadership With Jump To 82 RS Rating
Ligand Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 71 to 82. 
Via Investor's Business Daily
Why Digital Turbine's Stock Is Trading Higher Today
Digital Turbine Inc (NASDAQ: APPS) is trading higher Tuesday after it was announced the company is set to join the S&P MidCap 400. Digital Turbine will replace ... 
Via Benzinga
Topics Stocks
Exposures US Equities
Digital Turbine Added To S&P MidCap 400 Index
Media and mobile communications company Digital Turbine Inc (NASDAQ: 
Via Benzinga
Topics Stocks
Exposures US Equities
Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma
From Ligand Pharmaceuticals Incorporated
Via Business Wire
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
From Ligand Pharmaceuticals
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.